Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/AARTIPHARM stock hub

NSE/AARTIPHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/AARTIPHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

69.5B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/AARTIPHARM

In the news

Latest news · NSE/AARTIPHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E32.5

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC9.1

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/AARTIPHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

172

Groups with data

Currency

INR

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	2,162
Employees Change	67%
Employees Change Percent	3.2
Enterprise value	INR 75.7B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE0LRU01027
Last refreshed	2026-05-10
Market cap	INR 69.5B
Price	INR 767
Price currency	INR
Rev Per Employee	8,328,286.31x
Sector	Healthcare
Sic	2834
Symbol	nse/AARTIPHARM
Website	https://www.aartipharmalabs.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.08%
EV Earnings	35.39x
EV/EBIT	23.54x
EV/EBITDA	18.47x
EV/Sales	4.2x
P/B ratio	3.39x
P/E ratio	32.52x
P/S ratio	3.86x
PE Ratio3 Y	23.98x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	17.71%
EBITDA Margin	22.32%
Gross margin	51.29%
Gross Profit	INR 9.2B
Gross Profit Growth	0.96%
Gross Profit Growth Q	-1.09%
Gross Profit Growth3 Y	4.39%
Net Income	INR 2.1B
Net Income Growth	-14.27%
Net Income Growth Q	-35.19%
Net Income Growth Years	5%
Net Income Growth3 Y	0.31%
Pretax Margin	15.64%
Profit Margin	11.87%
Profit Per Employee	INR 988,657
Profitable Years	4
Roa5y	6.76
Roe5y	11.28
ROIC	9.08

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	4.51%
Cagr3y	25.26%
EPS Growth	-14.33
EPS Growth Q	-35.17
EPS Growth Years	5
EPS Growth3 Y	8
Revenue Growth	-12.47x
Revenue Growth Q	-19.62x
Revenue Growth Years	1x
Revenue Growth3 Y	-4.39x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 555.6M
Debt	INR 6.7B
Debt EBITDA	INR 1.66
Debt Equity	INR 0.33
Equity	INR 20.5B
Interest Coverage	8.71
Net Cash	INR -6.2B
Net Cash By Market Cap	INR -8.91
Net Debt EBITDA	INR 1.54
Net Debt Equity	INR 0.3
Tangible Book Value	INR 19.3B
Tangible Book Value Per Share	INR 213
WACC	6.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.1%
Dividend Growth	14.29%
Dividend Growth Years	3%
Dividend per share	INR 5
Dividend Years	4
Dividend Yield	0.65%
Ex Div Date	2026-02-16
Last Dividend	INR 1.5
Payout Frequency	Semi-Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	4.51%
200-day SMA	776.9
3Y total return	96.56%
50-day SMA	687.2
50-day SMA vs 200-day SMA	50under200
All Time High	971
All Time High Change	-21.01%
All Time High Date	2025-07-16
All Time Low	234.8
All Time Low Change	226.66%
All Time Low Date	2023-02-03
ATR	30.97
Beta	0.4
Beta1y	0.57
Beta2y	0.65
Ch YTD	1.94
High	789
High52	971
High52 Date	2025-07-16
High52ch	-21.01%
Low	763.8
Low52	585
Low52 Date	2026-03-30
Low52ch	31.11%
Ma50ch	11.61%
Price vs 200-day SMA	-1.27%
RSI	60.6
RSI Monthly	55.28
RSI Weekly	54.26
Sharpe ratio	0.31x
Sortino ratio	0.6
Total Return	0.55%
Tr YTD	2.16
Tr1m	18.05%
Tr1w	-4.85%
Tr3m	-1.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 3.2B
Operating Income Growth	-9.66
Operating Income Growth Q	-30.2
Operating Income Growth3 Y	2.3
Operating margin	17.71

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	47,897,510%
Shares Insiders	29.64%
Shares Institutions	18.44%
Shares Out	90,657,751
Shares Qo Q	-0.01%
Shares Yo Y	0.1%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	220,847.95x
Bv Per Share	225.7
Ch1m	18.05
Ch1w	-4.85
Ch1y	4.01
Ch3m	-1.26
Ch3y	93.88
Ch6m	-11.32
Change	-1.37%
Change From Open	-1.37
Close	777.7
Days Gap	0
Depreciation Amortization	829,854,500
Dollar Volume	111,912,203
Earnings Date	2026-05-08
EBIT	INR 3.2B
EBITDA	INR 4B
EPS	INR 23.56
F Score	2
Fiscal Year End	March
Founded	2,019
Graham Number	345.88617
Graham Upside	-54.9
Income Tax	INR 679.1M
Is Primary Listing	1
Last Earnings Date	2026-02-09
Last Report Date	2025-12-31
Lynch Fair Value	INR 118
Lynch Upside	-84.64
Ma150	741.2
Ma150ch	3.49%
Ma20	720
Ma20ch	6.52%
Open	777.7
Payment Date	2026-03-11
Position In Range	12.7
Price Date	2026-05-08
Price EBITDA	INR 17.28
Ptbv Ratio	3.6
Relative Volume	0.65x
Revenue	18,005,755,000x
Tax By Revenue	3.77x
Tax Rate	24.11%
Tr6m	-11.14%
Volume	145,909

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/AARTIPHARM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.7%

$5.00 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

3 consecutive years of growth

Total shareholder yield

+0.5%

Next ex-dividend date: 2026-02-16

Performance

NSE/AARTIPHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/AARTIPHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+18.4%

Share of float held by funds and institutions

Insider ownership

+29.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.1%

Negative means the company is buying back shares.

Technical

NSE/AARTIPHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

60.6

Neutral momentum band

Price vs 200-day MA

-1.3%

50/200-day relationship not available

Beta (5Y)

0.40

Less volatile than the market

Sharpe ratio

0.31

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/AARTIPHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/AARTIPHARM stock rating?

nse/AARTIPHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/AARTIPHARM analysis?

The full report lives at /stocks/nse/AARTIPHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/AARTIPHARM?

The latest report frames nse/AARTIPHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/AARTIPHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.